Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
Go back to Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)| AmerElite Solutions, Inc. New (NASDAQ: AMRX) | Delayed: 19.18 -0.07 (0.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.25 | 52 Week High | $0.19 | |||
| Open | $19.28 | 52 Week Low | $0.07 | |||
| Day High | $19.39 | P/E | N/A | |||
| Day Low | $18.94 | EPS | $-0.01 | |||
| Volume | 2,429,166 | |||||



